ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years
Hebing Chen
Matched on ORCID iD 0000-0003-4102-356X; OpenAlex author ID A5057117181. Sources: OpenAlex.
Their work
- Papers
- 6
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 20
2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper
Papers 6
- Feasibility of Dynamic Volume Perfusion CT for Treatment Response Monitoring in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.acra.2026.08.112↗
- ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. Co-author DOI 10.1016/j.mcp.2025.102030↗
- Guiding post-pancreaticoduodenectomy interventions for pancreatic cancer patients utilizing decision tree models. Co-author DOI 10.3389/fonc.2024.1399297↗
- Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. Co-author DOI 10.1080/21691401.2023.2264358↗
- Dynamic Interplay between Structural Variations and 3D Genome Organization in Pancreatic Cancer. Co-author DOI 10.1002/advs.202200818↗
- An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD4-mediated mechanisms. Co-author DOI 10.1038/s41467-022-33037-x↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Hong-Juan Yao · 3 shared papers, 2022–2025 · strength 0.49
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030↗
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Yuchen Shi · 3 shared papers, 2022–2025 · strength 0.49
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030↗
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Liang Li · 3 shared papers, 2022–2025 · strength 0.49
- Paper ANP32E expression in pancreatic cancer is associated with impaired gemcitabine efficacy and poor patient prognosis. DOI 10.1016/j.mcp.2025.102030↗
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Huadan Xue · 1 shared paper, 2026 · strength 0.36
- Xiaofei Zhou · 2 shared papers, 2022–2023 · strength 0.29
- Paper Study on tumour cell-derived hybrid exosomes as dasatinib nanocarriers for pancreatic cancer therapy. DOI 10.1080/21691401.2023.2264358↗
- Paper An EGFR/HER2-targeted conjugate sensitizes gemcitabine-sensitive and resistant pancreatic cancer through different SMAD… DOI 10.1038/s41467-022-33037-x↗
- Qifeng Xiao · 1 shared paper, 2025 · strength 0.20
- Chenyu Yuan · 1 shared paper, 2025 · strength 0.20
- Xiaohong Liu · 1 shared paper, 2025 · strength 0.20
- Shutong Yue · 1 shared paper, 2024 · strength 0.18
- Haixin Wang · 1 shared paper, 2024 · strength 0.18
- Yan Zhang · 1 shared paper, 2024 · strength 0.18
- Xiaohong Liu · 1 shared paper, 2023 · strength 0.16
- Xiaohao Zheng · 1 shared paper, 2022 · strength 0.16
- Chengfeng Wang · 1 shared paper, 2022 · strength 0.16
- Zongting Gu · 1 shared paper, 2022 · strength 0.16
- Yongxing Du · 1 shared paper, 2022 · strength 0.16
- Rong‐Guang Shao · 1 shared paper, 2022 · strength 0.13
- Rui Cao · 1 shared paper, 2022 · strength 0.13
- Yi Li · 1 shared paper, 2022 · strength 0.13
- Li Zhang · 1 shared paper, 2022 · strength 0.13
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.